Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease

Gilead Sciences Inc. knows a thing or two about developing successful liver disease therapies, since it owns the world's top two hepatitis C drugs in terms of sales, and now the company is attempting to dominate another liver disease with the purchase of Nimbus Apollo Inc. for up to $1.2bn.